Date: 2018-05-01
Type of information: Nomination
Compound: general manager and president
Company: BeiGene (China)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 1, 2018, BeiGene announced the appointment of Dr. Xiaobin Wu to the position of General Manager of China and President of BeiGene, Ltd., reporting to John Oyler, Founder, CEO and Chairman. Dr. Wu has more than 25 years of experience in the pharmaceutical industry including 17 years leading China operations of multinational companies, with expertise in integrated research and development, strategy, commercialization, and general management. He joins BeiGene from Pfizer China, where he served as Country Manager since 2009 and was the Regional President of Pfizer Essential Health for Greater China. Under Dr. Wu’s leadership, Pfizer expanded its portfolio and organization, grew sales meaningfully, initiated a range of innovative marketing programs, and established its position as a leading multinational pharmaceutical company in China.
- Prior to Pfizer, Dr. Wu served as President and Managing Director of Wyeth China and Hong Kong. Before Wyeth, he was General Manager of Bayer Healthcare in China. He started his career in 1992 in sales and marketing with Bayer in Germany.
- Dr. Wu also currently serves as a Vice Chairman of the China R&D-based Pharmaceutical Industry Association Committee (RDPAC).
- Dr. Wu holds a Ph.D. in Biochemistry and Pharmacology and a master’s degree in Molecular Biology from the University of Konstanz in Germany.
Financial terms:
Latest news:
Is general: Yes
